Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
2001 5
2002 2
2003 2
2004 1
2005 1
2006 3
2007 9
2008 1
2009 9
2010 4
2011 6
2012 1
2013 6
2014 10
2015 11
2016 11
2017 8
2018 6
2019 6
2020 10
2021 4
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Hypoxia and hypoxia response-associated molecular markers in esophageal cancer: A systematic review.
Peerlings J, Van De Voorde L, Mitea C, Larue R, Yaromina A, Sandeleanu S, Spiegelberg L, Dubois L, Lambin P, Mottaghy FM. Peerlings J, et al. Methods. 2017 Nov 1;130:51-62. doi: 10.1016/j.ymeth.2017.07.002. Epub 2017 Jul 10. Methods. 2017. PMID: 28705470 Review.
CONCLUSION: Evaluation of tumor micro-environmental conditions, such as intratumoral hypoxia, is important to predict treatment outcome and efficacy. Promising non-invasive imaging-techniques have been suggested to assess tumor hypoxia and hypoxia-associated …
CONCLUSION: Evaluation of tumor micro-environmental conditions, such as intratumoral hypoxia, is important to predict treatment outco …
Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles.
Peeters SG, Zegers CM, Yaromina A, Van Elmpt W, Dubois L, Lambin P. Peeters SG, et al. Q J Nucl Med Mol Imaging. 2015 Mar;59(1):39-57. Epub 2014 Dec 17. Q J Nucl Med Mol Imaging. 2015. PMID: 25517080 Review.
Furthermore, multiple studies describe the prognostic value of hypoxia PET imaging and the ability to monitor hypoxia during treatment. ...Also the feasibility studies for hypoxia guided intensity modulated radiation therapy and the patient stratification for …
Furthermore, multiple studies describe the prognostic value of hypoxia PET imaging and the ability to monitor hypoxia during t …
New ways to image and target tumour hypoxia and its molecular responses.
Dubois LJ, Niemans R, van Kuijk SJ, Panth KM, Parvathaneni NK, Peeters SG, Zegers CM, Rekers NH, van Gisbergen MW, Biemans R, Lieuwes NG, Spiegelberg L, Yaromina A, Winum JY, Vooijs M, Lambin P. Dubois LJ, et al. Radiother Oncol. 2015 Sep;116(3):352-7. doi: 10.1016/j.radonc.2015.08.022. Epub 2015 Aug 28. Radiother Oncol. 2015. PMID: 26324018 Free article. Review.
Tumour hypoxia and its molecular responses have been shown to be associated with poor prognosis. ...This review gives an overview of recent literature on hypoxia imaging markers currently used in clinical trials. Furthermore, recent progress made in targeting hyp …
Tumour hypoxia and its molecular responses have been shown to be associated with poor prognosis. ...This review gives an overview of …
Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma.
Zegers CM, van Elmpt W, Hoebers FJ, Troost EG, Öllers MC, Mottaghy FM, Lambin P. Zegers CM, et al. Acta Oncol. 2015;54(9):1378-84. doi: 10.3109/0284186X.2015.1062913. Epub 2015 Jul 27. Acta Oncol. 2015. PMID: 26213313
BACKGROUND: Tumour hypoxia and a high tumour metabolism increase radioresistance in patients with head and neck squamous cell carcinoma (HNSCC). The aim of this study was to evaluate the correlation between hypoxia ([(18)F]HX4 PET) and glucose metabolism ([(18)F]FDG …
BACKGROUND: Tumour hypoxia and a high tumour metabolism increase radioresistance in patients with head and neck squamous cell carcino …
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.
Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL, Scozzafava A, Supuran CT, Moser I, Jobst G, Busk M, Toustrup K, Overgaard J, Alsner J, Pouyssegur J, Chiche J, Mazure N, Marchiq I, Parks S, Ahmed A, Ashcroft M, Pastorekova S, Cao Y, Rouschop KM, Wouters BG, Koritzinsky M, Mujcic H, Cojocari D. Pettersen EO, et al. J Enzyme Inhib Med Chem. 2015;30(5):689-721. doi: 10.3109/14756366.2014.966704. Epub 2014 Oct 27. J Enzyme Inhib Med Chem. 2015. PMID: 25347767 Review.
Low density quantitative real-time polymerase chain reaction (qPCR)-based assays were developed measuring multiple hypoxia-responsive markers in parallel to identify tumour hypoxia-related patterns of gene expression. As possible targets for new therapy two main reg …
Low density quantitative real-time polymerase chain reaction (qPCR)-based assays were developed measuring multiple hypoxia-responsive …
Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.
Salem A, Asselin MC, Reymen B, Jackson A, Lambin P, West CML, O'Connor JPB, Faivre-Finn C. Salem A, et al. J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx160. J Natl Cancer Inst. 2018. PMID: 28922791 Review.
This review will summarize the role of hypoxia, highlight the potential of hypoxia as a therapeutic target, and outline past and ongoing hypoxia-targeted therapy trials in NSCLC. Evidence supporting radiotherapy dose painting based on hypoxia imaging w …
This review will summarize the role of hypoxia, highlight the potential of hypoxia as a therapeutic target, and outline past a …
Mitochondrial Dysfunction Inhibits Hypoxia-Induced HIF-1alpha Stabilization and Expression of Its Downstream Targets.
van Gisbergen MW, Offermans K, Voets AM, Lieuwes NG, Biemans R, Hoffmann RF, Dubois LJ, Lambin P. van Gisbergen MW, et al. Front Oncol. 2020 May 19;10:770. doi: 10.3389/fonc.2020.00770. eCollection 2020. Front Oncol. 2020. PMID: 32509579 Free PMC article.

Increased glycolysis was observed for cytoplasmic 143B mutant hybrid (m.3243A>G, >94.5%) cells (p < 0.05) and 143B mitochondrial DNA (mtDNA) depleted cells (p < 0.05). Upon hypoxia (0.2%, 16 h), genetic or pharmacological oxidative phosphorylation (OXPHOS) inhi

…

Increased glycolysis was observed for cytoplasmic 143B mutant hybrid (m.3243A>G, >94.5%) cells (p < 0.05) and 143B mitochondrial DN

…
Hypoxia PET Imaging with [18F]-HX4-A Promising Next-Generation Tracer.
Sanduleanu S, Wiel AMAV, Lieverse RIY, Marcus D, Ibrahim A, Primakov S, Wu G, Theys J, Yaromina A, Dubois LJ, Lambin P. Sanduleanu S, et al. Cancers (Basel). 2020 May 22;12(5):1322. doi: 10.3390/cancers12051322. Cancers (Basel). 2020. PMID: 32455922 Free PMC article. Review.
To date, a variety of methods are available for the assessment of tumor hypoxia, including the use of positron emission tomography (PET). ...The current review focusses on [18F]-HX4, a promising next-generation hypoxia PET tracer. After a brief history of its develo …
To date, a variety of methods are available for the assessment of tumor hypoxia, including the use of positron emission tomography (P …
Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape.
Hamis S, Kohandel M, Dubois LJ, Yaromina A, Lambin P, Powathil GG. Hamis S, et al. PLoS Comput Biol. 2020 Aug 3;16(8):e1008041. doi: 10.1371/journal.pcbi.1008041. eCollection 2020 Aug. PLoS Comput Biol. 2020. PMID: 32745136 Free PMC article.
Hypoxia-activated prodrugs (HAPs) present a conceptually elegant approach to not only overcome, but better yet, exploit intra-tumoural hypoxia. ...
Hypoxia-activated prodrugs (HAPs) present a conceptually elegant approach to not only overcome, but better yet, exploit intra-tumoura …
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.
Spiegelberg L, Houben R, Niemans R, de Ruysscher D, Yaromina A, Theys J, Guise CP, Smaill JB, Patterson AV, Lambin P, Dubois LJ. Spiegelberg L, et al. Clin Transl Radiat Oncol. 2019 Jan 18;15:62-69. doi: 10.1016/j.ctro.2019.01.005. eCollection 2019 Feb. Clin Transl Radiat Oncol. 2019. PMID: 30734002 Free PMC article.
To fully exploit the potential of hypoxia-activated prodrugs, hypoxia stratification of patients is needed. Here, we propose a biomarker-stratified enriched Phase III study design in which only biomarker-positive (i.e. hypoxia-positive) patients are randomize …
To fully exploit the potential of hypoxia-activated prodrugs, hypoxia stratification of patients is needed. Here, we propose a …
106 results